The FDA has approved a new freeze-dried formulation of Jynneos (smallpox and mpox vaccine, live, non-replicating).

A new report from GlobalData has raised concerns over the effectiveness of mpox vaccines for people living with HIV. Findings ...

As the FDA’s top biologics official, Peter Marks oversaw regulation of cell and gene therapies. The departure of Marks and ...

Jynneos was the first smallpox vaccine developed under Project BioShield, a program created by Congress in 2004 to accelerate ...

Yesterday the US Food and Drug Administration (FDA) approved a freeze-dried formulation of Bavarian Nordic's mpox vaccine, ...

A recent study has shown that one dose of Bavarian Nordic’s Jynneos vaccine was overall 58% effective at preventing mpox ...

The formulation allows for greater stockpiling, with Bavarian Nordic already working with the US Government to add to vaccine ...

Denmark's Bavarian Nordic said on Monday the U.S. Food and Drug Administration has approved a freeze-dried formulation of its ...

The Company has been contracted by the U.S Biomedical Advanced Research and Development Authority (BARDA) to develop and supply a freeze-dried version of JYNNEOS for stockpiling. Manufacturing under ...

Emergent BioSolutions struggles with declining revenues, rising competition, and weak growth prospects. Read why I rate EBS ...

Clade I, the culprit in the current 2025 version of global epidemic mpox, is highly transmissible and is spreading within families and among children, whereas the 2022 Clade II mpox - still spreading ...

Enhanced airport screening for travelers from endemic regions. Improve Access to Vaccination The JYNNEOS (Imvamune) vaccine has shown cross-protection against Clade I mpox. A targeted vaccination ...